Northwire Canada EditionFriday, October 16, 2026
Sign inSubscribe
Northwire
⌕
GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8% GOLD 4170.10 +1.5% SILVER 57.16 +2.3% COPPER 6.56 −1.5% OIL 97.97 +3.0% PALLADIUM 1136.00 +3.6% LUN 32.91 +0.6% DLP 0.290 −3.3% VCV 0.065 −13.3% GG 2.89 +1.4% NBLC 0.015 +0.0% SF 0.300 −4.8% ATY 0.215 +2.4% GHL 0.060 −7.7% STND 0.060 −7.7% B 0.550 −3.5% HBM 34.33 −0.5% NTR 98.77 −0.7% SGZ 0.035 +0.0% MKA 0.670 +0.0% LXM 0.175 −18.6% CLCH 1.08 −1.8%

Healthcare

Page 41
  1. Mar 30, 2026 · 07:01 · VIVI

    TempraMed’s Panama LOI Adds Another Geographic Checkbox as Stock Tests Multi-Month Lows Amid Unproven Commercial Traction

    TempraMed Signs LOI for Distribution Agreement in Panama, Expanding Central American Exposure

    01
  2. Mar 30, 2026 · 06:03 · ARCH

    Arch Biopartners Closes $600K Lifeline as Stock Tests 52-Week Lows Amid Dilution and Trial Rollout

    Arch Biopartners Arranges Non-Brokered Private Placement

    02
  3. Mar 30, 2026 · 03:05 · BNXT

    BioNxt Pivots to GLP-1 Thin-Film Race as Cladribine Trials Stall and Cash Burn Looms

    BioNxt Advances Semaglutide as First Application of Broad GLP-1 ODF Platform Strategy

    03
  4. Mar 27, 2026 · 15:15 · PRN

    Profound talks up Tulsa procedure milestone in Texas

    Profound talks up Tulsa procedure milestone in Texas

    04
  5. Mar 27, 2026 · 10:15 · VPT

    MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value

    MedTech's Edge: How AI and Remote Diagnostics Drive Scalable Value

    05
  6. Mar 27, 2026 · 08:10 · QNTM

    Quantum Biopharma's 2025 Audited Year End Financial Results Maintain 'No Going Concern' Status

    Quantum Biopharma's 2025 Audited Year End Financial Results Maintain 'No Going Concern' Status

    06
  7. Mar 27, 2026 · 07:45 · PRN

    Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure(TM) Milestone

    Profound Medical Congratulates Texas Prostate on Achieving 100th TULSA Procedure(TM) Milestone

    07
  8. Mar 27, 2026 · 07:00 · MSCL

    Satellos Reports 2025 Financial Results and Highlights Recent Company Progress

    Satellos Reports 2025 Financial Results and Highlights Recent Company Progress

    08
  9. Mar 26, 2026 · 23:46 · ALGO

    Light AI reports Financial Results for Three Months and Year ended December 31, 2025

    Light AI reports Financial Results for Three Months and Year ended December 31, 2025

    09
  10. Mar 26, 2026 · 17:34 · PHRM

    Pharmather applies for provisional PatchPrint patent

    Pharmather applies for provisional PatchPrint patent

    10
  11. Mar 26, 2026 · 17:17 · QNTM

    Quantum Biopharma appoints Napoli as trial investigator

    Quantum Biopharma appoints Napoli as trial investigator

    11
  12. Mar 26, 2026 · 08:01 · PHRM

    PharmaTher Introduces PatchPrint(TM) With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches

    PharmaTher Introduces PatchPrint(TM) With Provisional Patent Filing and Commercialization Strategy for Microneedle Patches

    12
  13. Mar 26, 2026 · 08:00 · QNTM

    Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis

    Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis

    13
  14. Mar 26, 2026 · 07:30 · EDT

    Spectral Medical Announces Fourth Quarter and Fiscal 2025 Results and Provides Corporate Update

    Spectral Medical Announces Fourth Quarter and Fiscal 2025 Results and Provides Corporate Update

    14
← Newer Older →